CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 500 enrolled
Drug / intervention
Vyndaqeldrug
Likely dose
Vyndaqel 20mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02146378
NCT02146378N/ACompleted

Vyndaqel Capsules Special Investigation -Investigation on Long-term Use-

Pfizer·observational·Posted May 23, 2014·Updated Feb 3, 2025

In Brief

An observational study evaluating Vyndaqel for Transthyretin Familial Amyloid Polyneuropathy. Completed, enrolled 500 participants.

Detailed Summary

The purpose of this study is to understand safety (e.g., occurrence of adverse drug reactions \[ADRs\]) and efficacy data on the long-term use of Vyndaqel Capsules (hereinafter referred to as Vyndaqel) in all patients who received this drug under actual use conditions after its marketing.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--

Timeline

N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMay 23, 2014
Enrollment StartJan 10, 2014
Primary CompletionMar 10, 2023
TodayJul 2, 2026
Enrollment to primary: 9.2 yearsPosted 12.1 years ago

Interventions

Vyndaqeldrug

20mg/day